Therapeutic targeting of the IL-13 pathway in skin inflammation

• Results Overview

  IL-13 plays a key role in atopic dermatitis, and drugs that block IL-13 (like tralokinumab and lebrikizumab) show promising results in treating moderate-to-severe eczema.

• Study Summary

  Num Participants:

  None

  Study Type:

  Review

  Control Group:

  None

  Efficacy End Points Treatment:

  None

  Efficacy End Points Control:

  None

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected